DaVita Inc., a prominent healthcare provider specializing in kidney dialysis services for patients with chronic kidney failure, has recently announced significant developments regarding its clinical offerings and internal corporate governance. Based in Denver, Colorado, the company has long been a staple in the healthcare services sector, maintaining its presence on the New York Stock Exchange since its public debut in October 1995.

In a major clinical expansion, DaVita has announced the nationwide rollout of its Expanded hemodialysis therapy. This specialized treatment is now available at all of the company’s centers across the United States. The therapy is designed to remove larger toxins from the bloodstream, a capability that holds significant potential for improving the overall quality of life for patients undergoing treatment. Early indicators suggest a successful integration of the service, with the company reporting rapid adoption among physicians and high uptake among the patient population.

Parallel to these clinical advancements, the company has addressed recent changes in beneficial ownership through a series of Form 4 filings submitted on November 15, 2026. These regulatory reports detail various transactions by several directors and officers within the organization. The filings indicate a pattern of routine acquisitions of common stock, with various directors either increasing or maintaining their holdings through direct purchases or indirect trusts. Notably, a filing by CEO Javier Rodriguez recorded the issuance of restricted shares held back for tax purposes.

As of the market close on November 16, 2026, DaVita Inc. was trading at 173 USD, with a market capitalization of approximately 10.96 billion USD. The company’s stock has experienced notable volatility over the past year, reaching a 52-week high of 247.49 USD in August 2026, following a 52-week low of 101 USD in January 2026. With a price-to-earnings ratio of 13.2, the company continues to navigate a complex landscape of clinical innovation and corporate restructuring within the global healthcare provider industry.